sarilumab
Sanofi’s arthritis treatment Kevzara secures NICE recommendation
September 25, 2017Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab
Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …
Sanofi and Regeneron score FDA approval for arthritis
May 23, 2017Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab
The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …
EU recommendation for Sanofi and Regeneron’s arthritis treatment
April 24, 2017Sales and Marketing Kevzara, NICE, sarilumab
Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
FDA rejects Sarilumab due to production facility issues
October 31, 2016Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab
The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …
GSK and J&J file rheumatoid arthritis treatment sirukumab in EU
September 13, 2016Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab
GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
August 1, 2016Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Sanofi’s rheumatoid arthritis biologic performs
May 22, 2015Sales and Marketing Sanofi, rheumatoid arthritis, sarilumab
French pharma giant Sanofi plans to submit its new rheumatoid arthritis biologic for regulatory approval in the US after it …
Sanofi eyes phase III move for sarilumab in rheumatoid arthritis
July 13, 2011Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab
Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
